食管及胃食管交界癌放化疗后胃出血发生率与剂量学预测因素
该研究回顾性分析了145例接受至少41.4 Gy放化疗且照射野包含胃的局部食管癌患者,中位处方剂量50.4 Gy。仅2例(1.4%)发生≥3级胃出血,唯一显著相关的剂量学因素为较高的胃Dmax(58.1和58.3 Gy),胃Dmax>58 Gy时出血风险增加(P<.05)。结论提示处方50.4 Gy时无需为预防出血而限制胃照射体积或剂量,但限制胃最大剂量<58 Gy可能避免出血。
要点
- 145例患者中仅2例(1.4%)发生≥3级胃出血。
- 胃Dmax>58 Gy与≥3级胃出血风险增加相关(P<.05)。
- 处方50.4 Gy时无需为预防出血而限制胃照射体积或剂量。
核心结论
- 食管癌放化疗处方50.4 Gy时,无需为预防出血而限制胃照射体积或剂量。
- 将胃最大剂量限制在<58 Gy可能避免出血,尤其对肝硬化等出血风险因素患者需谨慎。
研究设计与样本
- 回顾性分析145例接受至少41.4 Gy放化疗、照射野包含胃且未手术切除的局部食管或胃食管交界癌患者。
- 中位处方剂量50.4 Gy(范围41.4-56 Gy),收集中位胃Dmax 53.0 Gy(1.0-62.7 Gy)及胃V40、V45、V50 Gy等剂量体积参数,生成剂量体积直方图分析。
主要发现
- 2例(1.4%)发生放射性≥3级胃出血(GB3+),其胃Dmax分别为58.1和58.3 Gy,高于队列中位53 Gy。
- 另5例GB3+事件与记录的肿瘤进展相关,基于胃Dmax的Cox比例风险模型对GB3+发生有统计学意义。
- 时间-事件曲线和剂量体积图谱显示仅当胃Dmax>58 Gy时GB3+风险增加(P<.05)。
关键数值与推荐
- 中位处方剂量50.4 Gy(范围41.4-56 Gy)。
- 中位胃Dmax 53.0 Gy(1.0-62.7 Gy),中位胃V40、V45、V50 Gy分别为112 cm3(0-667 cm3)、84 cm3(0-632 cm3)、50 cm3(0-565 cm3)。
- 基于胃Dmax的Cox比例风险模型对GB3+发生有统计学意义,胃Dmax>58 Gy时GB3+风险增加(P<.05)。
临床怎么用
- 食管癌放化疗处方50.4 Gy时,无需为预防出血而刻意限制胃照射体积或剂量。
- 可考虑将胃最大剂量限制在<58 Gy以降低出血风险,尤其对肝硬化或使用非甾体抗炎药等出血风险因素患者需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine the incidence and predictors of gastric bleeding after chemoradiation for esophageal or gastroesophageal junction cancer. METHODS AND MATERIALS: We reviewed patients receiving chemoradiation to at least 41.4 Gy for localized esophageal cancer whose fields included the stomach and who did not undergo surgical resection. The primary endpoint was grade ≥3 gastric hemorrhage (GB3+). Comprehensive stomach dose-volume parameters were collected, and stomach dose-volume histograms were generated for analysis. RESULTS: A total of 145 patients met our inclusion criteria. Median prescribed dose was 50.4 Gy (range, 41.4-56 Gy). Median stomach Dmax was 53.0 Gy (1.0-62.7 Gy), and median stomach V40, V45, and V50 Gy were 112 cm3 (0-667 cm3), 84 cm3 (0-632 cm3), and 50 cm3 (0-565 cm3), respectively. Two patients (1.4%) developed radiation-induced GB3+. The only dosimetric factor that was significantly different for these patients was a higher stomach Dmax (58.1 and 58.3 Gy) than the cohort median (53 Gy). One of these patients also had cirrhosis, and the other had a history of nonsteroidal anti-inflammatory drug use. Five other patients had GB3+ events associated with documented tumor progression. A Cox proportional hazards model based on stomach Dmax with respect to the development of GB3+ was found to be statistically significant. Time-to-event curves and dose-volume atlases were generated, demonstrating an increased risk of GB3+ only when stomach Dmax was >58 Gy (P < .05). CONCLUSIONS: We observed a low rate of GB3+ events in patients who received chemoradiation to a median dose of 50.4 Gy to volumes that included a significant portion of the stomach. These results suggest that when prescribing 50.4 Gy for esophageal cancer, there is no need to minimize the irradiated gastric volume or dose for the sake of preventing bleeding complications. Limiting stomach maximum doses to <58 Gy may also avoid bleeding, and particular caution should be taken in patients with other risk factors for bleeding, such as cirrhosis.
引用
- Montovano M, Zhang M, Oh P, et al. Incidence and Dosimetric Predictors of Radiation-Induced Gastric Bleeding After Chemoradiation for Esophageal and Gastroesophageal Junction Cancer. Adv Radiat Oncol. 2021. PMID: 34195487. doi:10.1016/j.adro.2021.100648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。